National Bank of Canada’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $307K | Sell |
60,600
-9,800
| -14% | -$49.6K | ﹤0.01% | 1234 |
|
|
2025
Q1 | $372K | Buy |
70,400
+53,100
| +307% | +$281K | ﹤0.01% | 1132 |
|
|
2024
Q4 | $117K | Buy |
+17,300
| New | +$117K | ﹤0.01% | 1389 |
|
|
2024
Q3 | – | Sell |
-200
| Closed | -$1.49K | – | 2785 |
|
|
2024
Q2 | $1.49K | Sell |
200
-1,000
| -83% | -$7.43K | ﹤0.01% | 2300 |
|
|
2024
Q1 | $10.3K | Sell |
1,200
-1,950
| -62% | -$16.7K | ﹤0.01% | 1983 |
|
|
2023
Q4 | $31K | Buy |
3,150
+1,500
| +91% | +$14.8K | ﹤0.01% | 1735 |
|
|
2023
Q3 | $11.7K | Buy |
1,650
+1,500
| +1,000% | +$10.7K | ﹤0.01% | 1938 |
|
|
2023
Q2 | $1.12K | Hold |
150
| – | – | ﹤0.01% | 2366 |
|
|
2023
Q1 | $1K | Buy |
+150
| New | +$1K | ﹤0.01% | 2385 |
|
|
2022
Q4 | – | Sell |
-1,000
| Closed | – | – | 2679 |
|
|
2022
Q3 | $0 | Sell |
1,000
-2,000
| -67% | – | ﹤0.01% | 2642 |
|
|
2022
Q2 | $24K | Buy |
+3,000
| New | +$24K | ﹤0.01% | 1818 |
|